血红蛋白类氧载体的研究进展及应用前景*

doi:10.3969/j.issn.1671-2587.2024.02.019

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (2): 282-288.DOI: 10.3969/j.issn.1671-2587.2024.02.019

• 综述 • 上一篇

血红蛋白类氧载体的研究进展及应用前景^*

李洋^1,2, 杨明峰^1,2, 王莹^1,2, 张坚³, 刘嘉馨⁴, 孙保亮^1,2

¹山东第一医科大学（山东省医学科学院）第二附属医院山东泰安 271000;
²山东第一医科大学（山东省医学科学院）脑科学与类脑研究院山东济南 250117;
³中国医学科学院微循环研究所北京 100005;
⁴中国医学科学院输血研究所四川成都 610052

收稿日期:2024-01-10 出版日期:2024-04-20 发布日期:2024-04-23
通讯作者: 孙保亮,主要从事神经系统疾病防治以及神经损伤与修复研究,（E-mail）blsun88@163.com。共同通信作者：刘嘉馨,主要从事血液管理、血液代用品、生物医用材料及医疗器械研究,（E-mail）jxliu@ibt.pumc.edu.cn。
作者简介:李洋,主要从事脑血管疾病的研究,（E-mail）1805101580@qq.com。
基金资助:
*本课题受山东省自然科学基金重大基础研究项目（No.ZR2019ZD32）资助

Research Progress and Application Prospect of Hemoglobin-based Oxygen Carriers

LI Yang^1,2, YANG Mingfeng^1,2, WANG Ying^1,2, ZHANG Jian³, LIU Jiaxin⁴, SUN Baoliang^1,2

¹Second Affiliated Hospital, Shandong First Medical University & Shandong Academy of Medical Sciences, Taian, Shandong 271000;
²Institute of Brain Science and Brain-inspired Research, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong 250117;
³Institute of Microcirculation, Chinese Academy of Medical Sciences, Beijing 100005;
⁴Institute of Blood Transfusion, Chinese Academy of Medical Sciences, Peking Union Medical College, Chengdu 610052

Received:2024-01-10 Online:2024-04-20 Published:2024-04-23

摘要/Abstract

摘要： 红细胞输注已广泛应用于创伤救治、外科手术、输血治疗以及战伤急救等多个方面,但依然存在血液资源紧缺、储存期短、输前需交叉配型、可能经血传播病原体等问题。血红蛋白氧载体（hemoglobin-based oxygen carriers,HBOCs）是一类由无基质血红蛋白通过化学修饰等方法制备的可溶性纳米级具有携释氧功能的氧载体,能代替红细胞为体内各器官、组织输送氧气,且具有无血型和病毒传播风险、储存长,即时可用的特点,也称为红细胞代用品。本文旨在综述HBOCs研究的进展,同时探讨其在除替代红细胞输血治疗以外,针对其他如器官保存、脑缺血、肿瘤等治疗中的应用前景。

关键词: 红细胞代用品, 血红蛋白氧载体, 创伤, 贫血, 器官保存, 脑缺血, 肿瘤

Abstract: Red blood cell transfusion has been widely used in trauma treatment, surgery, anemia treatment, war wound emergency treatment and other aspects, but there are still problems such as shortage of blood resources, short storage period, cross-matching before transfusion, and possible transmission of pathogens through blood. Hemoglobin-based oxygen carriers (HBOCs) are a class of soluble nano-oxygen carriers prepared by chemical modification of matrix-free hemoglobin, which can replace red blood cells to transport oxygen to organs and tissues in the body. HBOCs have the characteristics of no blood group and virus transmission risk, long storage, and instant use, so they are also known as red blood cell substitutes. This paper aims to review the research progress of HBOCs, and explore their application prospects in organ preservation, cerebral ischemia, tumor treatment and other treatments in addition to the replacement of red blood cell transfusion.

Key words: Red Blood Cell Substitutes, Hemoglobin oxygen carrier, Trauma, Anemia, Organ preservation, Cerebral ischemia, Tumor

中图分类号:

R457

李洋, 杨明峰, 王莹, 张坚, 刘嘉馨, 孙保亮. 血红蛋白类氧载体的研究进展及应用前景^*[J]. 临床输血与检验, 2024, 26(2): 282-288.

LI Yang, YANG Mingfeng, WANG Ying, ZHANG Jian, LIU Jiaxin, SUN Baoliang. Research Progress and Application Prospect of Hemoglobin-based Oxygen Carriers[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 282-288.

参考文献

[1] HAFEEZ S,ZAIDI N U S S.Red blood cell substitutes:liposome encapsulated hemoglobin and magnetite nanoparticle conjugates as oxygen carriers[J].Int J Mol Sci,2023,24(2):1618.
[2] BIALAS C,MOSER C,SIMS C A.Artificial oxygen carriers and red blood cell substitutes:a historic overview and recent developments toward military and clinical relevance[J].J Trauma Acute Care Surg,2019,87(1S Suppl 1):S48-S58.
[3] COHEN M J,KUTCHER M,REDICK B,et al.Clinical and mechanistic drivers of acute traumatic coagulopathy[J].J Trauma Acute Care Surg,2013,75(1 Suppl 1):S40-S47.
[4] ZHANG Q,MA Y X,DAI Z,et al.Tracking research on hemoglobin-based oxygen carriers:a scientometric analysis and In-depth review[J].Drug Des Devel Ther,2023,17:2549-2571.
[5] JANSMAN M M T,HOSTA-RIGAU L.Recent and prominent examples of nano- and microarchitectures as hemoglobin-based oxygen carriers[J].Adv Colloid Interface Sci,2018,260:65-84.
[6] JOHNSTONE J E,MACLAREN L A,DOUCET J,et al.In vitro studies regarding the feasibility of bovine erythrocyte xenotransfusion[J].Xenotransplantation,2004,11(1):11-17.
[7] CAO M,WANG G Q,HE H L,et al.Hemoglobin-based oxygen carriers:potential applications in solid organ preservation[J].Front Pharmacol,2021,12:760215.
[8] LUPON E,LELLOUCH A G,ZAL F,et al.Combating hypoxemia in COVID-19 patients with a natural oxygen carrier,HEMO₂Life® (M101)[J].Med Hypotheses,2021,146:110421.
[9] KORTE E A,POZZI N,WARDRIP N,et al.Analytical interference of HBOC-201 (Hemopure,a synthetic hemoglobin-based oxygen carrier) on four common clinical chemistry platforms[J].Clin Chim Acta,2018,482:33-39.
[10] WHITAKER B,RAJBHANDARY S,KLEINMAN S,et al.Trends in United States blood collection and transfusion:results from the 2013 AABB Blood Collection,Utilization,and Patient Blood Management Survey[J].Transfusion,2016,56(9):2173-2183.
[11] TAGUCHI K,YAMASAKI K,MARUYAMA T,et al.Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers[J].J Funct Biomater,2017,8(1):11.
[12] BLACKBOURNE L H,BAER D G,EASTRIDGE B J,et al.Military medical revolution:prehospital combat casualty care[J].J Trauma Acute Care Surg,2012,73(6 Suppl 5):S372-S377.
[13] GU J S,CHANG T M S.Extraction of erythrocyte enzymes for the preparation of polyhemoglobin-catalase-superoxide dismutase[J].Artif Cells Blood Substit Immobil Biotechnol,2009,37(2):69-77.
[14] KEIPERT P E.Hemoglobin-based oxygen carrier (HBOC) development in trauma:previous regulatory challenges,lessons learned,and a path forward[J].Adv Exp Med Biol,2017,977:343-350.
[15] PIRES I S,SAVLA C,PALMER A F.Poly(ethylene glycol) surface-conjugated apohemoglobin as a synthetic heme scavenger[J].Biomacromolecules,2020,21(6):2155-2164.
[16] CHANG T M S.Blood replacement with nanobiotechnologically engineered hemoglobin and hemoglobin nanocapsules[J].Wiley Interdiscip Rev Nanomed Nanobiotechnol,2010,2(4):418-430.
[17] D'AGNILLO F,ALAYASH A I.Site-specific modifications and toxicity of blood substitutes.The case of diaspirin cross-linked hemoglobin[J].Adv Drug Deliv Rev,2000,40(3):199-212.
[18] MARTÍNEZ J L,LIU L F,PETRANOVIC D,et al.Engineering the oxygen sensing regulation results in an enhanced recombinant human hemoglobin production by Saccharomyces cerevisiae[J].Biotechnol Bioeng,2015,112(1):181-188.
[19] BANERJEE U,WOLFE S,O'BOYLE Q,et al.Scalable production and complete biophysical characterization of poly(ethylene glycol) surface conjugated liposome encapsulated hemoglobin (PEG-LEH)[J].PLoS One,2022,17(7):e0269939.
[20] SCOTT K L,LECAK J,ACKER J P.Biopreservation of red blood cells:past,present,and future[J].Transfus Med Rev,2005,19(2):127-142.
[21] MATTON A P M,BURLAGE L C,VAN RIJN R,et al.Normothermic machine perfusion of donor livers without the need for human blood products[J].Liver Transpl,2018,24(4):528-538.
[22] JAHR J S,MOALLEMPOUR M,LIM J C.HBOC-201,hemoglobin glutamer-250 (bovine),Hemopure (Biopure Corporation)[J].Expert Opin Biol Ther,2008,8(9):1425-1433.
[23] NATANSON C,KERN S J,LURIE P,et al.Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death:a meta-analysis[J].JAMA,2008,299(19):2304-2312.
[24] WEISKOPF R B,SILVERMAN T A.Balancing potential risks and benefits of hemoglobin-based oxygen carriers[J].Transfusion,2013,53(10):2327-2333.
[25] VRSELJA Z,DANIELE S G,SILBEREIS J,et al.Restoration of brain circulation and cellular functions hours post-mortem[J].Nature,2019,568(7752):336-343.
[26] YU B L,SHAHID M,EGORINA E M,et al.Endothelial dysfunction enhances vasoconstriction due to scavenging of nitric oxide by a hemoglobin-based oxygen carrier[J].Anesthesiology,2010,112(3):586-594.
[27] ZHANG J,CAO S Y,KWANSA H,et al.Transfusion of hemoglobin-based oxygen carriers in the carboxy state is beneficial during transient focal cerebral ischemia[J].J Appl Physiol (1985),2012,113(11):1709-1717.
[28] ALAYASH A I.Mechanisms of toxicity and modulation of hemoglobin-based oxygen carriers[J].Shock,2019,52(1S Suppl 1):41-49.
[29] VANDEGRIFF K D,YOUNG M A,LOHMAN J,et al.CO-MP4,a polyethylene glycol-conjugated haemoglobin derivative and carbon monoxide carrier that reduces myocardial infarct size in rats[J].Br J Pharmacol,2008,154(8):1649-1661.
[30] VOELKER M T,BERGMANN A,BUSCH T,et al.The effects of hemoglobin glutamer-200 and iNO on pulmonary vascular tone and arterial oxygenation in an experimental acute respiratory distress syndrome[J].Pulm Pharmacol Ther,2018,49:130-133.
[31] GEKKA M,ABUMIYA T,KOMATSU T,et al.Novel hemoglobin-based oxygen carrier bound with albumin shows neuroprotection with possible antioxidant effects[J].Stroke,2018,49(8):1960-1968.
[32] MAHBOUB P,ABURAWI M,KARIMIAN N,et al.The efficacy of HBOC-201 in ex situ gradual rewarming kidney perfusion in a rat model[J].Artif Organs,2020,44(1):81-90.
[33] BHATTACHARJEE R N,PATEL S V B,SUN Q Z,et al.Renal protection against ischemia reperfusion injury:hemoglobin-based oxygen carrier-201 versus blood as an oxygen carrier in ex vivo subnormothermic machine perfusion[J].Transplantation,2020,104(3):482-489.
[34] KAWAGUCHI A T,NAKAI K,FUKUMOTO D,et al.S-nitrosylated pegylated hemoglobin reduces the size of cerebral infarction in rats[J].Artif Organs,2009,33(2):183-188.
[35] SHIMBO D,ABUMIYA T,KURISU K,et al.Superior microvascular perfusion of infused liposome-encapsulated hemoglobin prior to reductions in infarctions after transient focal cerebral ischemia[J].J Stroke Cerebrovasc Dis,2017,26(12):2994-3003.
[36] GAO H,PENG H,YANG H,et al.Neurointerventional infusion of hemoglobin oxygen carrier prevents brain damage from acute cerebral ischemia in rats[J].Front Surg,2023,10:1050935.
[37] KAKEHATA J,YAMAGUCHI T,TOGASHI H,et al.Therapeutic potentials of an artificial oxygen-carrier,liposome-encapsulated hemoglobin,for ischemia/reperfusion-induced cerebral dysfunction in rats[J].J Pharmacol Sci,2010,114(2):189-197.
[38] HAN J Q,YU M H,DAI M,et al.Decreased expression of MDR1 in PEG-conjugated hemoglobin solution combined cisplatin treatment in a tumor xenograft model[J].Artif Cells Blood Substit Immobil Biotechnol,2012,40(4):239-244.
[39] BELCHER D A,JU J A,BAEK J H,et al.The quaternary state of polymerized human hemoglobin regulates oxygenation of breast cancer solid tumors:a theoretical and experimental study[J].PLoS One,2018,13(2):e0191275.
[40] LUCAS A,BELCHER D A,MUNOZ C,et al.Polymerized human hemoglobin increases the effectiveness of cisplatin-based chemotherapy in non-small cell lung cancer[J].Oncotarget,2020,11(42):3770-3781.
[41] LAMY M L,DAILY E K,BRICHANT J F,et al.Randomized trial of diaspirin cross-linked hemoglobin solution as an alternative to blood transfusion after cardiac surgery.The DCLHb Cardiac Surgery Trial Collaborative Group[J].Anesthesiology,2000,92(3):646-656.
[42] JAHR J S,AKHA A S,HOLTBY R J.Crosslinked,polym erized,and PEG-conjugated hemoglobin-based oxygen carriers:clinical safety and efficacy of recent and current products[J].Curr Drug Discov Technol,2012,9(3):158-165.
[43] GOULD S A,MOORE E E,HOYT D B,et al.The life-sustaining capacity of human polymerized hemoglobin when red cells might be unavailable[J].J Am Coll Surg,2002,195(4):445-452;discussion 452-455.
[44] CHENG D C H,MAZER C D,MARTINEAU R,et al.A phase II dose-response study of hemoglobin raffimer (Hemolink) in elective coronary artery bypass surgery[J].J Thorac Cardiovasc Surg,2004,127(1):79-86.
[45] DUBÉ G P,VRANCKX P,GREENBURG A G.HBOC-201:the multi-purpose oxygen therapeutic[J].EuroIntervention,2008,4(1):161-165.
[46] JAHR J S,MACKENZIE C,PEARCE L B,et al.HBOC-201 as an alternative to blood transfusion:efficacy and safety evaluation in a multicenter phase III trial in elective orthopedic surgery[J].J Trauma,2008,64(6):1484-1497.
[47] ZHOU W T,LI S,HAO S S,et al.An optimal polymerization process for low mean molecular weight HBOC with lower dimer[J].Artif Cells Nanomed Biotechnol,2015,43(3):148-151.
[48] SHEN Y S,ZHU W J,ZHAO M Y,et al.Study of the pharmacokinetics of polymerized porcine hemoglobin (pPolyHb)[J].Artif Cells Nanomed Biotechnol,2018,46(7):1373-1379.
[49] LEE N P,CHAN K T,CHOI M Y,et al.Oxygen carrier YQ23 can enhance the chemotherapeutic drug responses of chemoresistant esophageal tumor xenografts[J].Cancer Chemother Pharmacol,2015,76(6):1199-1207.
[50] KUANG L,ZHU Y,ZHANG J,et al.A novel cross-linked haemoglobin-based oxygen carrier is beneficial to sepsis in rats[J].Artif Cells Nanomed Biotechnol,2019,47(1):1496-1504.
[51] LI B,ZHANG J,SHEN C Y,et al.Application of polymerized porcine hemoglobin in the ex vivo normothermic machine perfusion of rat livers[J].Front Bioeng Biotechnol,2022,10:1072950.
[52] CHOW E,LAU J S H,WAI T,et al.The anti-tumoral effects of the oxygen carrier YQ23 in a triple-negative breast cancer syngeneic model[J].Transl Cancer Res,2021,10(2):656-668.

血红蛋白类氧载体的研究进展及应用前景^*

Research Progress and Application Prospect of Hemoglobin-based Oxygen Carriers

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	周仁龙, 李凌波, 闫岩, 唐丹丹. 血型CD36基因在泛癌中的综合分析[J]. 临床输血与检验, 2024, 26(2): 251-261.
[2]	尚玮, 汪德清. 纤维蛋白原在创伤性大失血救治中的研究进展^*[J]. 临床输血与检验, 2024, 26(2): 274-281.
[3]	赵兴丹, 翁艾罕. 极低出生体重儿输血及输血量的影响因素及其预测模型构建[J]. 临床输血与检验, 2023, 25(6): 758-766.
[4]	郭彬瀚, 叶萍, 陈剑, 凤婧, 江咏梅. 基于生物信息学探究红细胞储存时间对子宫内膜癌的影响[J]. 临床输血与检验, 2023, 25(6): 789-797.
[5]	芮雪, 蔡杰, 刘春都, 傅强, 张春, 何成涛. 肿瘤患者多次输血引起的联合抗体的鉴定策略分析——附1例报道[J]. 临床输血与检验, 2023, 25(6): 839-844.
[6]	钟馨, 邱浩川, 陈斯亮, 李朝晖, 毛怀东, 章俊. 低血红蛋白密度对血液透析贫血患者缺铁性贫血和铁缺乏的诊断价值分析^*[J]. 临床输血与检验, 2023, 25(5): 654-661.
[7]	江峰锦, 白乐, 余泽波, 王菡, 兰炯采, 胡雪. 自身免疫性溶血性贫血的诊疗进展[J]. 临床输血与检验, 2023, 25(5): 692-698.
[8]	高原, 高旭蓉, 高洁, 纪宏文. 冠状动脉旁路移植术患者围术期贫血防治的研究进展^*[J]. 临床输血与检验, 2023, 25(4): 555-558.
[9]	张怡, 卓海龙, 程晨, 陈怡静, 李静, 骆群. 血栓弹力图监测体外模拟创伤性低纤维蛋白原血症患者凝血功能变化[J]. 临床输血与检验, 2023, 25(3): 363-367.
[10]	中国输血协会免疫血液学专业委员会. 输血依赖型地中海贫血（TDT）患者临床输血中国专家共识[J]. 临床输血与检验, 2023, 25(2): 163-169.
[11]	夏悦昕, 刘志远, 宋文倩, 邵林楠, 梁晓华, 周世航. 先天性纯红细胞再生障碍性贫血氧化应激相关差异表达基因的生物信息学分析[J]. 临床输血与检验, 2023, 25(1): 82-87.
[12]	陈蕊, 吕孟兴, 尹加忠, 沈经纬, 熊荣, 白云艳, 周文彪, 王旭, 杨琦, 屈柯暄. 云南省地中海贫血儿童输血安全策略的研究^*[J]. 临床输血与检验, 2022, 24(6): 710-715.
[13]	胡恒雅, 周小玉. 术前贫血对先天性心脏病患儿围术期输血及预后的影响分析[J]. 临床输血与检验, 2022, 24(6): 721-724.
[14]	魏燕, 刘宽, 李祥军, 彭娟, 王瑞含, 刘久波. PRP治疗踝关节创伤性滑膜炎疗效观察^*[J]. 临床输血与检验, 2022, 24(6): 725-729.
[15]	魏超, 胥俊越, 席朝运, 赵锦阳, 关迺喆, 汪德清. 回顾性分析老年骨科患者用血特点及影响因素^*[J]. 临床输血与检验, 2022, 24(6): 736-742.